Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cellular Oncology
Published in: Cellular Oncology 2/2013

01-04-2013 | Review

Tumour-microenvironment interactions: role of tumour stroma and proteins produced by cancer-associated fibroblasts in chemotherapy response

Authors: Matthew David Hale, Jeremy David Hayden, Heike Irmgard Grabsch

Published in: Cellular Oncology | Issue 2/2013

Login to get access

Abstract

Background

Cytotoxic chemotherapy improves survival for some, but not all, cancer patients. Non-responders may experience unnecessary toxicity and cancer progression, thus creating an urgent need for biomarkers that can predict the response to chemotherapy. So far, the search for such biomarkers has primarily been focused on the cancer cells and less on their surrounding stroma. This stroma is known to act as a key regulator of tumour progression and, in addition, has been associated with drug delivery and drug efficacy. Fibroblasts represent the major cell type in cancer-associated stroma and they secrete extracellular matrix proteins as well as growth factors. This Medline-based literature review summarises the results from studies on epithelial cancers and aimed at investigating relationships between the quantity and quality of the intra-tumoral stroma, the cancer-associated fibroblasts, the proteins they produce and the concomitant response to chemotherapy. Biomarkers were selected for review that are known to affect cancer-related characteristics and patient prognosis.

Results

The current literature supports the hypothesis that biomarkers derived from the tumour stroma may be useful to predict response to chemotherapy. This notion appears to be related to the overall quantity and cellularity of the intra-tumoural stroma and the predominant constituents of the extracellular matrix.

Conclusion

Increasing evidence is emerging showing that tumour-stroma interactions may not only affect tumour progression and patient prognosis, but also the response to chemotherapy. The tumour stroma-derived biomarkers that appear to be most appropriate to determine the patient’s response to chemotherapy vary by tumour origin and the availability of pre-treatment tissue. For patients scheduled for adjuvant chemotherapy, the most promising biomarker appears to be the PLAU: SERPINE complex, whereas for patients scheduled for neo-adjuvant chemotherapy the tumour stroma quantity appears to be most relevant.
Literature
1.
2.
G. Chong, D. Cunningham, Oesophageal cancer: preoperative chemotherapy. Ann. Oncol. 15(Suppl 4), iv87–iv91 (2004)PubMedCrossRef
3.
N. Tamura, T. Hasebe, N. Okada, T. Houjoh, S. Akashi-Tanaka, C. Shimizu, T. Shibata, Y. Sasajima, M. Iwasaki, T. Kinoshita, Tumor histology in lymph vessels and lymph nodes for the accurate prediction of outcome among breast cancer patients treated with neoadjuvant chemotherapy. Cancer Sci. 100, 1823–1833 (2009)PubMedCrossRef
4.
The Cochrane Collaboration: Advanced Bladder Cancer Meta-analysis Collaboration, Neoadjuvant chemotherapy for invasive bladder cancer (Review). The Cochrane Library. (2008).
5.
E. Kent, M. Hussain, Neoadjuvant Therapy for Prostate Cancer: An Oncologist’s Perspective. Rev Urol. 5(Suppl 3), S28–S37 (2003)PubMed
6.
T. Delaunoit, S.R. Alberts, D.J. Sargent, E. Green, R.M. Goldberg, J. Krook, C. Fuchs, R.K. Ramanathan, S.K. Williamson, R.F. Morton, B.P. Findlay, Chemotherapy permits resection of metastatic colorectal cancer: experience from Intergroup N9741. Ann. Oncol. 16, 425–429 (2005)PubMedCrossRef
7.
Network National Comprehensive Cancer, Network National Comprehensive Cancer. Clinical practice guidelines in oncology, ovarian cancer including fallopian tube cancer and primary peritoneal cancer version 2. Clinical Practice Guidelines in Oncology. (2011).
8.
S. Heinrich, M. Schäfer, A. Weber, T.F. Hany, U. Bhure, B.C. Pestalozzi, P. Clavien, Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic cancer without increasing morbidity: results of a prospective phase II trial. Ann. Surg. 248, 1014–1022 (2008)PubMedCrossRef
9.
S. Burdett, L. Stewart, Rydzewska, Chemotherapy and surgery versus surgery alone in non-small cell lung cancer. Cochrane Database Syst Rev. (2007).
10.
J. Neoptolemos, J. Dunn, D. Stocken, J. Almond, K. Link, H. Beger, C. Bassi, M. Falconi, P. Pederzoli, C. Dervenis, L. Fernandez-Cruz, F. Lacaine, A. Pap, D. Spooner, D. Kerr, H. Friess, M. Büchler, Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet. 358, 1576–1585 (2001)PubMedCrossRef
11.
J. Pignon, H. Tribodet, G. Scagliotti, J. Douillard, F. Shepherd, R. Stephens, A. Dunant, V. Torri, R. Rosell, L. Seymour, S.G. Spiro, E. Rolland, R. Fossati, D. Aubert, K. Ding, D. Waller, T. Le Chevalier, Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J. Clin. Oncol. 26, 3552–3559 (2008)PubMedCrossRef
12.
G. Bonadonna, E. Brusamolino, P. Valagussa, A. Rossi, L. Brugnatelli, C. Brambilla, M. De Lena, G. Tancini, E. Bajetta, R. Musumeci, U. Veronesi, Combination chemotherapy as an adjuvant treatment in operable breast cancer. N. Engl. J. Med. 294, 405–410 (1976)PubMedCrossRef
13.
R. Gray, J. Barnwell, C. McConkey, R. Hills, N. Williams, D. Kerr, Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 370, 2020–2029 (2007)PubMedCrossRef
14.
S. Wöhrer, M. Raderer, M. Hejna, Palliative chemotherapy for advanced gastric cancer. Ann. Oncol. 15, 1585–1595 (2004)PubMedCrossRef
15.
P. Simmonds, Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group. BMJ 321, 531–535 (2000)PubMedCrossRef
16.
I. Smith, Palliative chemotherapy for advanced non-small cell lung cancer. BMJ. 308, 429–430 (1994)PubMedCrossRef
17.
T. Petit, C. Borel, J.P. Ghnassia, J.F. Rodier, A. Escande, R. Mors, P. Haegelé, Chemotherapy response of breast cancer depends on HER-2 status and anthracycline dose intensity in the neoadjuvant setting. Clin. Cancer Res. 7, 1577–1581 (2001)PubMed
18.
F. Penault-Llorca, A. Vincent-Salomon, Roles of the pathologist in neoadjuvant chemotherapy: evaluation of response, prognostic and predictive factors. Ann Pathol. 23, 555–563 (2003)PubMed
19.
M.G. Daidone, R. Silvestrini, A. Luisi, M. Mastore, E. Benini, S. Veneroni, C. Brambilla, L. Ferrari, M. Greco, S. Andreola, Changes in biological markers after primary chemotherapy for breast cancers. Int. J. Cancer. 61, 301–305 (1995)PubMedCrossRef
20.
V. Cavaillès, A. Gompel, M.C. Portois, S. Thénot, N. Mabon, F. Vignon, Comparative activity of pulsed or continuous estradiol exposure on gene expression and proliferation of normal and tumoral human breast cells. J. Mol. Endocrinol. 28, 165–175 (2002)PubMedCrossRef
21.
22.
M. Allen, J. Jones, Jekyll and Hyde: the role of the microenvironment on the progression of cancer. J. Pathol. 223, 162–176 (2011)PubMed
23.
B. Elenbaas, R.A. Weinberg, Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation. Exp. Cell Res. 264, 169–184 (2001)PubMedCrossRef
24.
T.D. Tlsty, P.W. Hein, Know thy neighbor: stromal cells can contribute oncogenic signals. Curr. Opin. Genet. Dev. 11, 54–59 (2001)PubMedCrossRef
25.
A.F. Olumi, G.D. Grossfeld, S.W. Hayward, P.R. Carroll, T.D. Tlsty, G.R. Cunha, Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 59, 5002–5011 (1999)PubMed
26.
H. Kiaris, I. Chatzistamou, C. Kalofoutis, H. Koutselini, C. Piperi, A. Kalofoutis, Tumour-stroma interactions in carcinogenesis: basic aspects and perspectives. Mol. Cell. Biochem. 261, 117–122 (2004)PubMedCrossRef
27.
A. Orimo, P.B. Gupta, D.C. Sgroi, F. Arenzana-Seisdedos, T. Delaunay, R. Naeem, V.J. Carey, A.L. Richardson, R A Weinberg, Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 121, 335–348 (2005)PubMedCrossRef
28.
N.P. West, M. Dattani, P. Mcshane, G. Hutchins, J. Grabsch, W. Mueller, D. Treanor, P. Quirke, The proportion of tumour cells is an independent predictor for survival in colorectal cancer patients. Br. J. Cancer. 102, 1519–1523 (2010)PubMedCrossRef
29.
A. Labiche, N. Heutte, P. Herlin, J. Chasle, P. Gauduchon, N. Elie, Stromal compartment as a survival prognostic factor in advanced ovarian carcinoma. Int. J. Gynecol. Cancer. 20, 28–33 (2010)PubMedCrossRef
30.
Y. Wu, H. Grabsch, T. Ivanova, I.B. Tan, J. Murray, C.H. Ooi, A.I. Wright, Nicholas P West, G.G.A. Hutchins, J. Wu, M. Lee, J. Lee, J.H. Koo, K.G. Yeoh, N. van Grieken, B. Ylstra, S.Y. Rha, J.A. Ajani, J.H. Cheong, S.H. Noh, et al., Comprehensive genomic meta-analysis identifies intra-tumoural stroma as a predictor of survival in patients with gastric cancer. Gut. (2012).
31.
E.M. De Kruijf, J.G.H. van Nes, C.J.H. van de Velde, H. Putter, V.T.H.B.M. Smi, G.J. Liefers, P.J.K. Kuppen, R.A. Tollenaar, W.E. Mesker, Tumor-stroma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triple-negative carcinoma patients. Breast Cancer Res. Treat. 125, 687–696 (2011)PubMedCrossRef
32.
E.F.W. Courrech Staal, V.T.H.B.M. Smit, M.-L.F. van Velthuysen, J.M.J. Spitzer-Naaykens, M.W.J.M. Wouters, W.E. Mesker, R.A. Tollenaar, J.W. van Sandick, Reproducibility and validation of tumour stroma ratio scoring on oesophageal adenocarcinoma biopsies. Eur. J. Cancer. 47, 375–382 (2011)PubMedCrossRef
33.
Y. Zhang, H. Tang, J. Cai, T. Zhang, J. Guo, D. Feng, Z. Wang, Ovarian cancer-associated fibroblasts contribute to epithelial ovarian carcinoma metastasis by promoting angiogenesis, lymphangiogenesis and tumor cell invasion. Cancer Lett. 303, 47–55 (2011)PubMedCrossRef
34.
35.
T. Sethi, R.C. Rintoul, S.M. Moore, A.C. MacKinnon, D. Salter, C. Choo, E.R. Chilvers, I. Dransfield, S.C. Donnelly, R. Strieter, C. Haslett, Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat. Med. 5, 662–668 (1999)PubMedCrossRef
36.
F. Andre, N. Berrada, C. Desmedt, Implication of tumor microenvironment in the resistance to chemotherapy in breast cancer patients. Curr Opin Oncol. 22, 547–551 (2010)PubMedCrossRef
37.
A. Ostman, M. Augsten, Cancer-associated fibroblasts and tumor growth–bystanders turning into key players. Curr. Opin. Genet. Dev. 19, 67–73 (2009)PubMedCrossRef
38.
K. Pietras, K. Rubin, T. Sjöblom, T. Sjo, E. Buchdunger, M. Sjo, Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res. 62, 5476–5484 (2002)PubMed
39.
K. Pietras, A. Östman, M. Sjöquist, M. Sjo, O. Arne, E. Buchdunger, R.K. Reed, C. Heldin, K. Rubin, Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res. 61, 2929–2934 (2001)PubMed
40.
M. Sonnenberg, H. van der Kuip, S. Haubeis, P. Fritz, W. Schroth, G. Friedel, W. Simon, T.E. Mürdter, W.E. Aulitzky, Highly variable response to cytotoxic chemotherapy in carcinoma-associated fibroblasts (CAFs) from lung and breast. BMC cancer. 8, 364 (2008)PubMedCrossRef
41.
D. Lafkas, G. Trimis, A.G. Papavassiliou, Hippokratis Kiaris, P53 mutations in stromal fibroblasts sensitize tumors against chemotherapy. Int. J. Cancer. 123, 967–971 (2008)PubMedCrossRef
42.
I. Nakajima, Immunohistochemical study of the extracellular matrix in non-small cell lung cancer: relation to lymph node metastasis and prognosis. Hokkaido Igaku Zasshi. 66, 356–368 (1991)PubMed
43.
W.E. Mesker, J.M.C. Junggeburt, K. Szuhai, P. de Heer, H. Morreau, H.J. Tanke, R.A. Tollenaar, The carcinoma-stromal ratio of colon carcinoma is an independent factor for survival compared to lymph node status and tumor stage. Cell. Oncol. 29, 387–398 (2007)PubMed
44.
A.M. Maeshima, T. Niki, A. Maeshima, T. Yamada, H. Kondo, Y. Matsuno, Modified scar grade: a prognostic indicator in small peripheral lung adenocarcinoma. Cancer. 95, 2546–2554 (2002)PubMedCrossRef
45.
E.F.W. Courrech Staal, M.W.J.M. Wouters, J.W. van Sandick, M.M. Takkenberg, V.T.H.B.M. Smit, J.M.C. Junggeburt, J.M.J. Spitzer-Naaykens, T. Karsten, H.H. Hartgrink, W.E. Mesker, R.A. Tollenaar, The stromal part of adenocarcinomas of the oesophagus: does it conceal targets for therapy? Eur. J. Cancer 46, 720–728 (2010)PubMedCrossRef
46.
N. Yanagisawa, R. Li, D. Rowley, H. Liu, D. Kadmon, B.J. Miles, T.M. Wheeler, G.E. Ayala, Stromogenic prostatic carcinoma pattern (carcinomas with reactive stromal grade 3) in needle biopsies predicts biochemical recurrence-free survival in patients after radical prostatectomy. Human pathology. 39, 282–291 (2008)PubMedCrossRef
47.
G. Ayala, J.A. Tuxhorn, T.M. Wheeler, A. Frolov, P.T. Scardino, M. Ohori, M. Wheeler, J. Spitler, D.R. Rowley, Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer. Clin. Cancer Res. 9, 4792–4801 (2003)PubMed
48.
F. Xing, J. Saidou, K. Watabe, Cancer associated fibroblasts (CAFs) in tumor microenvironment. Front. Biosci. 15, 166–179 (2010)PubMedCrossRef
49.
O. De Wever, P. Demetter, M. Mareel, M. Bracke, Stromal myofibroblasts are drivers of invasive cancer growth. Int. J. Cancer. 123, 2229–2238 (2008)PubMedCrossRef
50.
K. Pietras, A. Ostman, Hallmarks of cancer: interactions with the tumor stroma. Exp. Cell Res. 316, 1324–1331 (2010)PubMedCrossRef
51.
O.E. Franco, A.K. Shaw, D.W. Strand, S.W. Hayward, Cancer associated fibroblasts in cancer pathogenesis. Semin. Cell Dev. Biol. 21, 33–39 (2010)PubMedCrossRef
52.
K. Räsänen, A. Vaheri, Activation of fibroblasts in cancer stroma. Exp. Cell Res. 316, 2713–2722 (2010)PubMedCrossRef
53.
T. Hasebe, S. Sasaki, S. Imoto, A. Ochiai, Highly proliferative fibroblasts forming fibrotic focus govern metastasis of invasive ductal carcinoma of the breast. Mod. Pathol. 14(325–37) (2001)
54.
T. Hasebe, H. Tsuda, S. Hirohashi, Y. Shimosato, Y. Tsubono, H. Yamamoto, K. Mukai, Fibrotic focus in infiltrating ductal carcinoma of the breast: a significant histopathological prognostic parameter for predicting the long-term survival of the patients. Breast Cancer Res. Treat. 49(195–208) (1998)
55.
T. Hasebe, S. Sasaki, S. Imoto, K. Mukai, T. Yokose, A. Ochiai, Prognostic significance of fibrotic focus in invasive ductal carcinoma of the breast: a prospective observational study. Mod. Pathol. 15(502–16) (2002)
56.
J.P.A. Baak, C.G.A. Colpaert, P.J. van Diest, E. Janssen, B. van Diermen, E. Albernaz, P.B. Vermeulen, E.A. Van Marck, Multivariate prognostic evaluation of the mitotic activity index and fibrotic focus in node-negative invasive breast cancers. Eur. J. Cancer. 41, 2093–2101 (2005)PubMedCrossRef
57.
C. Colpaert, P. Vermeulen, P. van Beest, G. Goovaerts, J. Weyler, P. Van Dam, L. Dirix, E. Van Marck, Intratumoral hypoxia resulting in the presence of a fibrotic focus is an independent predictor of early distant relapse in lymph node-negative breast cancer patients. Histopathology. 39, 416–425 (2001)PubMedCrossRef
58.
T. Hasebe, S. Sasaki, S. Imoto, A. Ochiai, Proliferative activity of intratumoral fibroblasts is closely correlated with lymph node and distant organ metastases of invasive ductal carcinoma of the breast. Am. J. Pathol. 156(1701–10) (2000)
59.
C. Wenger, V. Ellenrieder, B. Alber, U. Lacher, A. Menke, H. Hameister, M. Wilda, T. Iwamura, H.G. Beger, G. Adler, T.M. Gress, Expression and differential regulation of connective tissue growth factor in pancreatic cancer cells. Oncogene. 18, 1073–1080 (1999)PubMedCrossRef
60.
L.F. Lau, S.C. Lam, The CCN family of angiogenic regulators: the integrin connection. Exp. Cell Res. 248, 44–57 (1999)PubMedCrossRef
61.
F. Yang, J.A. Tuxhorn, S.J. Ressler, S.J. McAlhany, T.D. Dang, D.R. Rowley, Stromal expression of connective tissue growth factor promotes angiogenesis and prostate cancer tumorigenesis. Cancer Res. 65, 8887–8895 (2005)PubMedCrossRef
62.
K.S. Frazier, G.R. Grotendorst, Expression of connective tissue growth factor mRNA in the fibrous stroma of mammary tumors. Int J Biochem Cell Biol. 29, 153–161 (1997)PubMedCrossRef
63.
A. Koliopanos, Helmut Friess, F.F. di Mola, W.-H. Tang, D. Kubulus, D. Brigstock, A. Zimmermann, M.W. Büchler, Connective tissue growth factor gene expression alters tumor progression in esophageal cancer. World J Surg. 26, 420–427 (2002)PubMedCrossRef
64.
A.B. Kasaragod, M.S. Lucia, G. Cabirac, G.R. Grotendorst, K.R. Stenmark, Connective tissue growth factor expression in pediatric myofibroblastic tumors. Pediatr. Dev. Pathol. 4, 37–45
65.
T. Shakunaga, T. Ozaki, N. Ohara, K. Asaumi, T. Doi, K. Nishida, A. Kawai, T. Nakanishi, M. Takigawa, H. Inoue, Expression of connective tissue growth factor in cartilaginous tumors. Cancer. 89, 1466–1473 (2000)PubMedCrossRef
66.
M.-Y. Wang, P.-S. Chen, E. Prakash, H.-C. Hsu, H.-Y. Huang, M.-T. Lin, K.-J. Chang, M.-L. Kuo, Connective tissue growth factor confers drug resistance in breast cancer through concomitant up-regulation of Bcl-xL and cIAP1. Cancer Res. 69, 3482–3491 (2009)PubMedCrossRef
67.
M.P. Alfaro, D.L. Deskins, M. Wallus, J. Dasgupta, J.M. Davidson, L.B. Nanney, M. A Guney, M. Gannon, P.P. Young, A physiological role for connective tissue growth factor in early wound healing. Lab. Invest. [Epub ahead of print] (2012).
68.
J. Taylor-Papadimitriou, J. Burchell, J. Hurst, Production of fibronectin by normal and malignant human mammary epithelial cells. Cancer Res. 41, 2491–2500 (1981)PubMed
69.
C.-W. Pan, Z.-J. Shen, T.-T. Wu, X.-Y. Tang, M. Wang, J. Sun, Y. Shao, Cell adhesion to fibronectin induces mitomycin C resistance in bladder cancer cells. BJU international. 104, 1774–1779 (2009)PubMedCrossRef
70.
F. Thomas, J.M.P. Holly, R. Persad, A. Bahl, C.M. Perks, Fibronectin confers survival against chemotherapeutic agents but not against radiotherapy in DU145 prostate cancer cells: involvement of the insulin like growth factor-1 receptor. Prostate. 70, 856–865 (2010)PubMed
71.
P.S. Hodkinson, T. Elliott, W.S. Wong, R.C. Rintoul, A.C. Mackinnon, C. Haslett, T. Sethi, ECM overrides DNA damage-induced cell cycle arrest and apoptosis in small-cell lung cancer cells through beta1 integrin-dependent activation of PI3-kinase. Cell Death Differ. 13, 1776–1788 (2006)PubMedCrossRef
72.
H. Miyamoto, T. Murakami, K. Tsuchida, H. Sugino, H. Miyake, S. Tashiro, Tumor-stroma interaction of human pancreatic cancer: acquired resistance to anticancer drugs and proliferation regulation is dependent on extracellular matrix proteins. Pancreas. 28, 38–44 (2004)PubMedCrossRef
73.
W.S. Argraves, L.M. Greene, M.A. Cooley, W.M. Gallagher, Fibulins: physiological and disease perspectives. EMBO reports. 4, 1127–1131 (2003)PubMedCrossRef
74.
A.J. Obaya, S. Rua, A. Moncada-Pazos, S. Cal, The dual role of fibulins in tumorigenesis. Cancer letters. 325, 132–138 (2012)PubMedCrossRef
75.
S.M. Pupa, S. Giuffré, F. Castiglioni, L. Bertola, M. Cantú, I. Bongarzone, P. Baldassari, R. Mortarini, W.S. Argraves, A. Anichini, S. Menard, E. Tagliabue, Regulation of breast cancer response to chemotherapy by fibulin-1. Cancer Res. 67, 4271–4277 (2007)PubMedCrossRef
76.
A. Sadr-Nabavi, J. Ramser, J. Volkmann, J. Naehrig, F. Wiesmann, B. Betz, H. Hellebrand, S. Engert, S. Seitz, R. Kreutzfeld, T. Sasaki, N. Arnold, R. Schmutzler, M. Kiechle, D. Niederacher, N. Harbeck, E. Dahl, A. Meindl, Decreased expression of angiogenesis antagonist EFEMP1 in sporadic breast cancer is caused by aberrant promoter methylation and points to an impact of EFEMP1 as molecular biomarker. Int. J. Cancer. 124, 1727–1735 (2009)PubMedCrossRef
77.
E.F. Roark, D.R. Keene, C.C. Haudenschild, S. Godyna, C.D. Little, W S Argraves, The association of human fibulin-1 with elastic fibers: an immunohistological, ultrastructural, and RNA study. J. Histochem. Cytochem. 43, 401–411 (1995)PubMedCrossRef
78.
A.R. Albig, J.R. Neil, W.P. Schiemann, Fibulins 3 and 5 antagonize tumor angiogenesis in vivo. Cancer Res. 66, 2621–2629 (2006)PubMedCrossRef
79.
R.K. Sironen, M. Tammi, R. Tammi, P.K. Auvinen, M. Anttila, V.-M. Kosma, Hyaluronan in human malignancies. Exp. Cell Res. 317, 383–391 (2011)PubMedCrossRef
80.
R.H. Tammi, A. Kultti, Veli-Matti Kosma, R. Pirinen, P. Auvinen, M.I. Tammi, Hyaluronan in human tumors: pathobiological and prognostic messages from cell-associated and stromal hyaluronan. Semin. Cancer Biol. 18, 288–295 (2008)PubMedCrossRef
81.
P. Gibbs, P.R. Clingan, V. Ganju, A.H. Strickland, S.S. Wong, N.C. Tebbutt, C.R. Underhill, R.M. Fox, S.P. Clavant, J. Leung, M. Pho, T.J. Brown, Hyaluronan-Irinotecan improves progression-free survival in 5-fluorouracil refractory patients with metastatic colorectal cancer: a randomized phase II trial. Cancer Chemother. Pharmacol. 67, 153–163 (2011)PubMedCrossRef
82.
Y. Xie, K.L. Aillon, S. Cai, J.M. Christian, N.M. Davies, C.J. Berkland, M.L. Forrest, Pulmonary delivery of cisplatin-hyaluronan conjugates via endotracheal instillation for the treatment of lung cancer. Int J Pharm. 392, 156–163 (2010)PubMedCrossRef
83.
S. Misra, S. Ghatak, B.P. Toole, Regulation of MDR1 expression and drug resistance by a positive feedback loop involving hyaluronan, phosphoinositide 3-kinase, and ErbB2. J. Biol. Chem. 280, 20310–20315 (2005)PubMedCrossRef
84.
P. Auvinen, R. Tammi, J. Parkkinen, M. Tammi, U. Agren, R. Johansson, P. Hirvikoski, M. Eskelinen, V.M. Kosma, Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival. Am. J. Pathol. 156(529–36) (2000)
85.
R. Pirinen, R. Tammi, M. Tammi, P. Hirvikoski, J.J. Parkkinen, R. Johansson, J. Böhm, S. Hollmén, V.M. Kosma, Prognostic value of hyaluronan expression in non-small-cell lung cancer: Increased stromal expression indicates unfavorable outcome in patients with adenocarcinoma. Int. J. Cancer. 95(12–7) (2001)
86.
K. Matsumoto, K. Date, H. Ohmichi, T. Nakamura, Hepatocyte growth factor in lung morphogenesis and tumor invasion: role as a mediator in epithelium-mesenchyme and tumor-stroma interactions. Cancer Chemother. Pharmacol. 38(Suppl), S42–S47 (1996)PubMedCrossRef
87.
J. Yamashita, M. Ogawa, S. Yamashita, K. Nomura, M. Kuramoto, T. Saishoji, Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer. Cancer. 54, 1630–1633 (1994)
88.
Q. Zeng, S. Chen, Z. You, Y. Fan, T.E. Carey, D. Saims, C.-Y. Wang, Hepatocyte growth factor inhibits anoikis in head and neck squamous cell carcinoma cells by activation of ERK and Akt signaling independent of NFkappa. B. J. Biol. Chem 277, 25203–25208 (2002)CrossRef
89.
S. Fan, J.A. Wang, R.Q. Yuan, S. Rockwell, J. Andres, A. Zlatapolskiy, I.D. Goldberg, E.M. Rosen, Scatter factor protects epithelial and carcinoma cells against apoptosis induced by DNA-damaging agents. Oncogene. 17, 131–141 (1998)PubMedCrossRef
90.
M. Mildner, L. Eckhart, B. Lengauer, E. Tschachler, Hepatocyte growth factor/scatter factor inhibits UVB-induced apoptosis of human keratinocytes but not of keratinocyte-derived cell lines via the phosphatidylinositol 3-kinase/AKT pathway. J. Biol. Chem. 277, 14146–14152 (2002)PubMedCrossRef
91.
A. Rasola, Hepatocyte growth factor sensitizes human ovarian carcinoma cell lines to paclitaxel and cisplatin. Cancer Res. 64, 1744–1750 (2004)PubMedCrossRef
92.
L.A. Shuman Moss, S. Jensen-Taubman, W.G. Stetler-Stevenson, Matrix metalloproteinases: changing roles in tumor progression and metastasis. Am. J. Pathol. 181, 1895–1899 (2012)PubMedCrossRef
93.
R. Poulsom, M. Pignatelli, W.G. Stetler-Stevenson, L.A. Liotta, P.A. Wright, R.E. Jeffery, J.M. Longcroft, L. Rogers, G.W. Stamp, Stromal expression of 72 kda type IV collagenase (MMP-2) and TIMP-2 mRNAs in colorectal neoplasia. Am. J. Pathol. 141(389–96) (1992)
94.
C. Pyke, E. Ralfkiaer, K. Tryggvason, K. Danø, Messenger RNA for two type IV collagenases is located in stromal cells in human colon cancer. Am. J. Pathol. 142, 359–365 (1993)PubMed
95.
H. Liu, T. Zhang, X. Li, J. Huang, B. Wu, X. Huang, Y. Zhou, J. Zhu, J. Hou, Predictive value of MMP-7 expression for response to chemotherapy and survival in patients with non-small cell lung cancer. Cancer Sci. 99(2185–92) (2008)
96.
G.I. Murray, M.E. Duncan, P. O’Neil, J.A. McKay, W.T. Melvin, J.E. Fothergill, Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer. J. Pathol. 185, 256–261 (1998)PubMedCrossRef
97.
B. Fingleton, T. Vargo-Gogola, H.C. Crawford, L.M. Matrisian, Matrilysin [MMP-7] expression selects for cells with reduced sensitivity to apoptosis. Neoplasia. 3, 459–68
98.
N. Mitsiades, W.H. Yu, V. Poulaki, M. Tsokos, I. Stamenkovic, Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity. Cancer Res. 61, 577–581 (2001)PubMed
99.
V. Almendro, E. Ametller, S. García-Recio, O. Collazo, I. Casas, J.M. Augé, J. Maurel, P. Gascón, The role of MMP7 and its cross-talk with the FAS/FASL system during the acquisition of chemoresistance to oxaliplatin. PloS ONE. 4, e4728 (2009)PubMedCrossRef
100.
M. Egeblad, Z. Werb, New functions for the matrix metalloproteinases in cancer progression. Nature reviews. Nature reviews. Cancer. 2, 161–174 (2002)PubMedCrossRef
101.
Y. Jiang, I.D. Goldberg, Y.E. Shi, Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 21, 2245–2252 (2002)PubMedCrossRef
102.
M.N. Holten-Andersen, U. Hansen, N. Brünner, H.J. Nielsen, M. Illemann, B.S. Nielsen, Localization of tissue inhibitor of metalloproteinases 1 (TIMP-1) in human colorectal adenoma and adenocarcinoma. Int. J. Cancer. 113, 198–206 (2005)PubMedCrossRef
103.
A.-S. Schrohl, M.E. Meijer-van Gelder, M.N. Holten-Andersen, I.J. Christensen, M.P. Look, H.T. Mouridsen, N. Brünner, J.A. Foekens, Primary tumor levels of tissue inhibitor of metalloproteinases-1 are predictive of resistance to chemotherapy in patients with metastatic breast cancer. Clin. Cancer Res. 12, 7054–7058 (2006)PubMedCrossRef
104.
G.L. Willemoe, P.B. Hertel, A. Bartels, M.-B. Jensen, E. Balslev, B.B. Rasmussen, H. Mouridsen, B. Ejlertsen, N. Brünner, Lack of TIMP-1 tumour cell immunoreactivity predicts effect of adjuvant anthracycline-based chemotherapy in patients (n=647) with primary breast cancer. A Danish Breast Cancer Cooperative Group Study. Eur. J. Cancer. 45, 2528–2536 (2009)PubMedCrossRef
105.
N.M. Sørensen, P. Byström, I.J. Christensen, A. Berglund, H.J. Nielsen, N. Brünner, B. Glimelius, TIMP-1 is significantly associated with objective response and survival in metastatic colorectal cancer patients receiving combination of irinotecan, 5-fluorouracil, and folinic acid. Clin. Cancer Res 13, 4117–4122 (2007)PubMedCrossRef
106.
K.D. Steffensen, M. Waldstrøm, R.K. Christensen, A. Bartels, N. Brünner, A. Jakobsen, Lack of relationship between TIMP-1 tumour cell immunoreactivity, treatment efficacy and prognosis in patients with advanced epithelial ovarian cancer. BMC cancer. 10, 185 (2010)PubMedCrossRef
107.
A.D. Bradshaw, Diverse biological functions of the SPARC family of proteins. The international journal of biochemistry & cell biology. 44, 480–488 (2012)CrossRef
108.
I.T. Tai, M.J. Tang, SPARC in cancer biology: its role in cancer progression and potential for therapy. Drug resistance updates: reviews and commentaries in antimicrobial and anticancer chemotherapy. 11, 231–246 (2008)
109.
M. Rahman, A.P.K. Chan, I.T. Tai, A peptide of SPARC interferes with the interaction between caspase8 and Bcl2 to resensitize chemoresistant tumors and enhance their regression in vivo. PloS ONE. 6, e26390 (2011)PubMedCrossRef
110.
M.J. Tang, I.T. Tai, A novel interaction between procaspase 8 and SPARC enhances apoptosis and potentiates chemotherapy sensitivity in colorectal cancers. J. Biol. Chem. 282, 34457–34467 (2007)PubMedCrossRef
111.
J.M. Chan, S.H. Ho, I.T. Tai, Secreted protein acidic and rich in cysteine-induced cellular senescence in colorectal cancers in response to irinotecan is mediated by P53. Carcinogenesis. 31, 812–819 (2010)PubMedCrossRef
112.
C. Atorrasagasti, M. Malvicini, J.B. Aquino, L. Alaniz, M. Garcia, M. Bolontrade, M. Rizzo, O.L. Podhajcer, G. Mazzolini, Overexpression of SPARC obliterates the in vivo tumorigenicity of human hepatocellular carcinoma cells. Int. J. Cancer. 126, 2726–2740 (2010)PubMed
113.
I.T. Tai, M. Dai, D.A. Owen, L.B. Chen, Genome-wide expression analysis of therapy-resistant tumors reveals SPARC as a novel target for cancer therapy. J. Clin. Invest. 115, 1492–1502 (2005)PubMedCrossRef
114.
S.L. Bull Phelps, J. Carbon, A. Miller, E. Castro-Rivera, S. Arnold, R.A. Brekken, J.S. Lea, Secreted protein acidic and rich in cysteine as a regulator of murine ovarian cancer growth and chemosensitivity. Am. J. Obstet. Gynecol 200, 180.e1–7 (2009)CrossRef
115.
H.-C. Jeung, S.Y. Rha, C.K. Im, S.J. Shin, J.B. Ahn, W.I. Yang, J.K. Roh, S.H. Noh, H.C. Chung, A randomized phase 2 study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy. Cancer. 117, 2050–2057 (2011)PubMedCrossRef
116.
A. Francki, K. Motamed, T.D. McClure, M. Kaya, C. Murri, D.J. Blake, J.G. Carbon, E.H. Sage, SPARC regulates cell cycle progression in mesangial cells via its inhibition of IGF-dependent signaling. J. Cell. Biochem. 88, 802–811 (2003)PubMedCrossRef
117.
B.J. Schiemann, J.R. Neil, W.P. Schiemann, SPARC inhibits epithelial cell proliferation in part through stimulation of the transforming growth factor-beta-signaling system. Mol. Biol. Cell. 14, 3977–3988 (2003)PubMedCrossRef
118.
A. Francki, A.D. Bradshaw, J.A. Bassuk, C.C. Howe, W.G. Couser, E.H. Sage, SPARC regulates the expression of collagen type I and transforming growth factor-beta1 in mesangial cells. J. Cell. Biochem. 274(32145–52) (1999)
119.
M. Bernfield, M. Götte, P.W. Park, O. Reizes, M.L. Fitzgerald, J. Lincecum, M. Zako, Functions of cell surface heparan sulfate proteoglycans. Annu. Rev. Biochem. 68, 729–777 (1999)PubMedCrossRef
120.
121.
T. Maeda, C.M. Alexander, A. Friedl, Induction of syndecan-1 expression in stromal fibroblasts promotes proliferation of human breast cancer cells. Cancer Res. 64, 612–621 (2004)PubMedCrossRef
122.
B.J. Burbach, Y. Ji, A.C. Rapraeger, Syndecan-1 ectodomain regulates matrix-dependent signaling in human breast carcinoma cells. Exp. Cell Res. 300, 234–247 (2004)PubMedCrossRef
123.
M. Barbareschi, P. Maisonneuve, D. Aldovini, M.G. Cangi, L. Pecciarini, F. Angelo Mauri, S. Veronese, O. Caffo, A. Lucenti, P.D. Palma, E. Galligioni, C. Doglioni, High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis. Cancer. 98, 474–483 (2003)PubMedCrossRef
124.
C. Martin Götte, M. Kersting, J. Ruggiero, A.H. Tio, L. Tulusan, P. Kiesel, Wülfing, Predictive value of syndecan-1 expression for the response to neoadjuvant chemotherapy of primary breast cancer. Anticancer Res. 26, 621–627 (2006)PubMed
125.
E. Tsanou, E. Ioachim, E. Briasoulis, A. Charchanti, K. Damala, V. Karavasilis, N. Pavlidis, N.J. Agnantis, Clinicopathological study of the expression of syndecan-1 in invasive breast carcinomas. correlation with extracellular matrix components. J. Exp. Clin. Cancer Res. 23, 641–650 (2004)PubMed
126.
E.J. Kantelhardt, M. Vetter, M. Schmidt, C. Veyret, D. Augustin, V. Hanf, C. Meisner, D. Paepke, M. Schmitt, F. Sweep, G. von Minckwitz, P.-M. Martin, F. Jaenicke, C. Thomssen, N. Harbeck, Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6 × FEC versus 3 × FEC/3 × Docetaxel. BMC cancer. 11, 140 (2011)PubMedCrossRef
127.
E. Dublin, A. Hanby, N.K. Patel, R. Liebman, D. Barnes, Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma. Fibroblastic expression has strong associations with tumor pathology. Am. J. Pathol. 157, 1219–1227 (2000)PubMedCrossRef
128.
N. Harbeck, R.E. Kates, M. Schmitt, Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination. J. Clin. Oncol. 20(1000–7) (2002)
129.
N. Harbeck, R.E. Kates, M.P. Look, M. Kiechle, F. Ja, M. Schmitt, J.A. Foekens, Enhanced Benefit from Adjuvant Chemotherapy in Breast Cancer Patients Classified High-Risk according to Urokinase-type Plasminogen Activator (uPA) and Plasminogen Activator Inhibitor Type 1 (n = 3424. Cancer Res. 62(4617–22) (2002)
130.
P. Manders, V.C.G. Tjan-Heijnen, P.N. Span, N. Grebenchtchikov, A.J. Geurts-Moespot, D.T.H. van Tienoven, L.V.A.M. Beex, F.C.G.J. Sweep, The complex between urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-I) independently predicts response to first-line endocrine therapy in advanced breast cancer. Thromb. Haemost. 91, 514–521 (2004)PubMed
131.
S. Borstnar, A. Sadikov, B. Mozina, T. Cufer, High levels of uPA and PAI-1 predict a good response to anthracyclines. Breast Cancer Res. Treat. 121, 615–624 (2010)PubMedCrossRef
132.
P. Manders, Predictive impact of urokinase-type plasminogen activator: plasminogen activator inhibitor type-1 complex on the efficacy of adjuvant systemic therapy in primary breast cancer. Cancer Res. 64, 659–664 (2004)PubMedCrossRef
133.
S. Ohno, M. Tachibana, T. Fujii, S. Ueda, H. Kubota, N. Nagasue, Role of stromal collagen in immunomodulation and prognosis of advanced gastric carcinoma. Int. J. Cancer. 97, 770–774 (2002)PubMedCrossRef
134.
N. Harbeck, R.E. Kates, M. Schmitt, K. Gauger, M. Kiechle, F. Jänicke, C. Thomssen, M.P. Look, J.A. Foekens, Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer. Clin. Breast Cancer 5, 348–352 (2004)PubMedCrossRef
135.
S. McAllister, A. Gifford, A. Greiner, S. Kelleher, M. Saelzler, T. Ince, F. Reinhardt, L. Harris, B. Hylander, E. Repasky, R. Weinberg, Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell. 133, 994–1005 (2008)PubMedCrossRef
136.
A.S. Schrohl, I.J. Christensen, A.N. Pedersen, V. Jensen, H. Mouridsen, G. Murphy, J.A. Foekens, N. Brunner, Mads Nikolaj Holten-Andersen, Tumor tissue concentrations of the proteinase inhibitors tissue inhibitor of metalloproteinases-1 (TIMP-1) and plasminogen activator inhibitor type 1 (PAI-1) are complementary in determining prognosis in primary breast cancer. Mol. Cell Proteomics. 2(164–72) (2003)
137.
F. Jänicke, A. Prechtl, C. Thomssen, N. Harbeck, C. Meisner, M. Untch, C.G. Sweep, H.K. Selbmann, H. Graeff, M. Schmitt, Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J. Natl. Cancer Inst. 93(913–20) (2001)
138.
C. Chuaysri, P. Thuwajit, A. Paupairoj, S. Chau-In, T. Suthiphongchai, C. Thuwajit, Alpha-smooth muscle actin-positive fibroblasts promote biliary cell proliferation and correlate with poor survival in cholangiocarcinoma. Oncol. Rep. 21, 957–969 (2009)PubMed
139.
T. Tsujino, I. Seshimo, Hirofumi Yamamoto, C.Y. Ngan, K. Ezumi, I. Takemasa, M. Ikeda, M. Sekimoto, N. Matsuura, M. Monden, Stromal myofibroblasts predict disease recurrence for colorectal cancer. Clin. Cancer Res. 13, 2082–2090 (2007)PubMedCrossRef
140.
M. Erkan, C.W. Michalski, S. Rieder, C. Reiser-Erkan, I. Abiatari, A. Kolb, N.A. Giese, I. Esposito, H. Friess, J. Kleeff, The activated stroma index is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma. Clin. Gastroenterol. Hepatol. 6, 1155–1161 (2008)PubMedCrossRef
141.
H. Zhong, A.M. De Marzo, E. Laughner, M. Lim, D.A. Hilton, D. Zagzag, P. Buechler, W.B. Isaacs, G.L. Semenza, J.W. Simons, Overexpression of hypoxia-inducible factor 1 alpha in common human cancers and their metastases. Cancer Res. 59, 5830–5835 (1999)PubMed
142.
D.M. Brizel, G.S. Sibley, L.R. Prosnitz, R.L. Scher, M.W. Dewhirst, Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int. J. Radiat. Oncol. Biol. Phys. 38, 285–289 (1997)PubMedCrossRef
143.
K. Sundfør, H. Lyng, E.K. Rofstad, Tumour hypoxia and vascular density as predictors of metastasis in squamous cell carcinoma of the uterine cervix. Br. J. Cancer. 78, 822–827 (1998)PubMedCrossRef
144.
M. Bacac, P. Provero, N. Mayran, J.-C. Stehle, C. Fusco, I. Stamenkovic, A mouse stromal response to tumor invasion predicts prostate and breast cancer patient survival. PloS ONE. 1, e32 (2006)PubMedCrossRef
145.
K. Utispan, P. Thuwajit, Y. Abiko, K. Charngkaew, A. Paupairoj, S. Chau-in, C. Thuwajit, Gene expression profiling of cholangiocarcinoma-derived fibroblast reveals alterations related to tumor progression and indicates periostin as a poor prognostic marker. Mol. Cancer. 9, 13 (2010)PubMedCrossRef
146.
T. Yamanashi, Y. Nakanishi, G. Fujii, Y. Akishima-Fukasawa, Y. Moriya, Y. Kanai, M. Watanabe, S. Hirohashi, Podoplanin expression identified in stromal fibroblasts as a favorable prognostic marker in patients with colorectal carcinoma. Oncology. 77, 53–62 (2009)PubMedCrossRef
147.
M. Leivonen, J. Lundin, S. Nordling, K. von Boguslawski, C. Haglund, Prognostic value of syndecan-1 expression in breast cancer. Oncology. 67, 11–18 (2004)PubMedCrossRef
148.
J.R. Infante, H. Matsubayashi, N. Sato, J. Tonascia, A.P. Klein, T.A. Riall, C. Yeo, C. Iacobuzio-Donahue, M. Goggins, Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J. Clin. Oncol. 25, 319–325 (2007)PubMedCrossRef
149.
A.H. Ree, V.A. Florenes, J.P. Berg, G.M. Maelandsmo, J.M. Nesland, O. Fodstad, High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases. Clin. Cancer Res. 3, 1623–1628 (1997)PubMed
150.
K. McCarthy, T. Maguire, G. McGreal, E. McDermott, N. O’Higgins, M.J. Duffy, High levels of tissue inhibitor of metalloproteinase-1 predict poor outcome in patients with breast cancer. Int. J. Cancer. 84, 44–48 (1999)PubMedCrossRef
151.
M.P. Look, W.L.J. van Putten, M.J. Duffy, N. Harbeck, I.J. Christensen, C. Thomssen, R. Kates, F. Spyratos, M. Fernö, S. Eppenberger-Castori, C.G.J.F. Sweep, K. Ulm, J. Peyrat, P. Martin, H. Magdelenat, N. Brünner, C. Duggan, B.W. Lisboa, P. Bendahl, V. Quillien et al., Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J. Natl. Cancer Inst 94, 116–128 (2002)PubMedCrossRef
152.
P.A. Andreasen, L. Kjøller, L. Christensen, M.J. Duffy, The urokinase-type plasminogen activator system in cancer metastasis: a review. Int. J. Cancer. 72, 1–22 (1997)PubMedCrossRef
153.
M. Schmitt, N. Harbeck, C. Thomssen, O. Wilhelm, V. Magdolen, U. Reuning, K. Ulm, H. Höfler, F. Jänicke, H. Graeff, Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy. Thromb. Haemost. 78(285–96) (1997)
154.
M.J. Duffy, T.M. Maguire, E.W. McDermott, N. O’Higgins, Urokinase plasminogen activator: a prognostic marker in multiple types of cancer. J Surg Oncol. 71(130–5) (1999)
155.
C.Y. Ngan, H. Yamamoto, I. Seshimo, T. Tsujino, M. Man-i, J.-I. Ikeda, K. Konishi, I. Takemasa, M. Ikeda, M. Sekimoto, N. Matsuura, M. Monden, Quantitative evaluation of vimentin expression in tumour stroma of colorectal cancer. Br. J. Cancer 96, 986–992 (2007)PubMedCrossRef
156.
S. Al-Saad, K. Al-Shibli, T. Donnem, M. Persson, R.M. Bremnes, L.-T. Busund, The prognostic impact of NF-kappaB p105, vimentin, E-cadherin and Par6 expression in epithelial and stromal compartment in non-small-cell lung cancer. Br. J. Cancer. 99, 1476–1483 (2008)PubMedCrossRef
157.
L.-K. Liu, X.-Y. Jiang, X.-X. Zhou, D.-M. Wang, X.-L. Song, H.-B. Jiang, Upregulation of vimentin and aberrant expression of E-cadherin/beta-catenin complex in oral squamous cell carcinomas: correlation with the clinicopathological features and patient outcome. Mod. Pathol. 23, 213–224 (2010)PubMedCrossRef
158.
S. Otsuki, M. Inokuchi, M. Enjoji, T. Ishikawa, Y. Takagi, K. Kato, H. Yamada, K. Kojima, K. Sugihara, Vimentin expression is associated with decreased survival in gastric cancer. Oncol. Rep. 25, 1235–1242 (2011)PubMed
159.
T. Hasebe, H. Tsuda, Y. Tsubono, S. Imoto, K. Mukai, Fibrotic focus in invasive ductal carcinoma of the breast: a histopathological prognostic parameter for tumor recurrence and tumor death within three years after the initial operation. Jpn. J. Cancer Res. 88(590–9) (1997)
160.
A. Neesse, P. Michl, K.K. Frese, C. Feig, N. Cook, M.A. Jacobetz, M.P. Lolkema, M. Buchholz, K.P. Olive, T.M. Gress, D.A. Tuveson, Stromal biology and therapy in pancreatic cancer. Gut 60, 861–868 (2011)PubMedCrossRef
161.
I.G. Schauer, A.K. Sood, S. Mok, Cancer-associated fibroblasts and their putative role in potentiating the initiation and development of epithelial ovarian cancer. Neoplasia. 13, 393–405 (2011)PubMed
162.
H. Breuninger, G. Schaumburg-Lever, J. Holzschuh, H.P. Horny, Desmoplastic squamous cell carcinoma of skin and vermilion surface: a highly malignant subtype of skin cancer. Cancer. 79, 915–919 (1997)PubMedCrossRef
163.
L.A. Hazlehurst, W.S. Dalton, Mechanisms associated with cell adhesion mediated drug resistance (CAM-DR) in hematopoietic malignancies. Cancer Metastasis Rev. 20, 43–50 (2001)PubMedCrossRef
164.
H.F. Dvorak, Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med. 315, 1650–1659 (1986)PubMedCrossRef
165.
S. Grotegut, R. Kappler, S. Tarimoradi, F. Lehembre, Hepatocyte growth factor protects hepatoblastoma cells from chemotherapy-induced apoptosis by AKT activation. Int. J. Oncol. 36, 1261–1267 (2010)PubMed
Metadata
Title
Tumour-microenvironment interactions: role of tumour stroma and proteins produced by cancer-associated fibroblasts in chemotherapy response
Authors
Matthew David Hale
Jeremy David Hayden
Heike Irmgard Grabsch
Publication date
01-04-2013
Publisher
Springer Netherlands
Published in
Cellular Oncology / Issue 2/2013
Print ISSN: 2211-3428
Electronic ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-013-0127-7

Other articles of this Issue 2/2013

Cellular Oncology 2/2013 Go to the issue

Original Paper

Chromosome 1q25.3 copy number alterations in primary breast cancers detected by multiplex ligation-dependent probe amplification and allelic imbalance assays and its comparison with fluorescent in situ hybridization assays

Original Paper

SLUG silencing increases radiosensitivity of melanoma cells in vitro

Original Paper

Restoration of klotho expression induces apoptosis and autophagy in hepatocellular carcinoma cells

Original Paper

Epigenetic control of HNF-4α in colon carcinoma cells affects MUC4 expression and malignancy

Original Paper

CD81 is a candidate tumor suppressor gene in human gastric cancer

Original Paper

Abrogation of galectin-4 expression promotes tumorigenesis in colorectal cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits